Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) EBITDA (2019 - 2025)

Volitionrx's EBITDA history spans 9 years, with the latest figure at -$6.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 10.05% year-over-year to -$6.2 million; the TTM value through Dec 2025 reached -$24.2 million, up 10.81%, while the annual FY2025 figure was -$24.2 million, 10.81% up from the prior year.
  • EBITDA reached -$6.2 million in Q4 2025 per VNRX's latest filing, down from -$5.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$5.4 million in Q3 2025 to a low of -$9.5 million in Q2 2023.
  • Average EBITDA over 5 years is -$7.3 million, with a median of -$7.5 million recorded in 2022.
  • Peak YoY movement for EBITDA: tumbled 67.89% in 2021, then soared 36.2% in 2024.
  • A 5-year view of EBITDA shows it stood at -$8.8 million in 2021, then grew by 15.49% to -$7.4 million in 2022, then fell by 18.46% to -$8.8 million in 2023, then skyrocketed by 36.2% to -$5.6 million in 2024, then decreased by 10.05% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for VNRX's EBITDA are -$6.2 million (Q4 2025), -$5.4 million (Q3 2025), and -$6.9 million (Q2 2025).